NantHealth Inc (NH) Given New $5.00 Price Target at Jefferies Group LLC
NantHealth Inc (NYSE:NH) had its price objective cut by Jefferies Group LLC from $5.50 to $5.00 in a research report report published on Wednesday morning. They currently have a buy rating on the stock. Jefferies Group also issued estimates for NantHealth’s Q3 2017 earnings at ($0.24) EPS, Q4 2017 earnings at ($0.28) EPS, FY2017 earnings at ($1.44) EPS, Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.20) EPS, Q3 2018 earnings at ($0.19) EPS and FY2018 earnings at ($0.78) EPS.
Separately, Canaccord Genuity restated a buy rating and issued a $6.00 price objective (down previously from $8.00) on shares of NantHealth in a research report on Monday, August 21st. Five analysts have rated the stock with a buy rating, NantHealth has a consensus rating of Buy and an average price target of $8.55.
NantHealth (NH) traded down 4.04% on Wednesday, hitting $2.85. The stock had a trading volume of 166,880 shares. NantHealth has a 12-month low of $2.84 and a 12-month high of $15.80. The company’s market cap is $347.55 million. The company’s 50 day moving average price is $3.88 and its 200-day moving average price is $4.43.
NantHealth (NYSE:NH) last posted its earnings results on Thursday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.32. NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The firm had revenue of $26.23 million during the quarter, compared to the consensus estimate of $31.28 million. During the same quarter last year, the firm posted ($0.15) EPS. The business’s revenue was down 16.7% on a year-over-year basis. Equities research analysts anticipate that NantHealth will post ($0.70) EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of NH. TIAA CREF Investment Management LLC boosted its position in NantHealth by 68.6% in the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after buying an additional 8,217 shares during the period. Alliancebernstein L.P. bought a new position in NantHealth during the second quarter valued at $102,000. Bank of America Corp DE boosted its position in NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock valued at $125,000 after buying an additional 19,694 shares during the period. GSA Capital Partners LLP bought a new position in NantHealth during the second quarter valued at $121,000. Finally, Teachers Advisors LLC boosted its position in NantHealth by 351.8% in the second quarter. Teachers Advisors LLC now owns 31,578 shares of the company’s stock valued at $134,000 after buying an additional 24,588 shares during the period.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.